Over the past few years, Medtronic ( NYSE: MDT ) has faced significant challenges, including a pandemic-induced slowdown, relatively slow revenue growth, and economic issues that impacted its financial results. Throughout it all, Medtronic's diabetes care business has consistently been one of its ...

India's better-than-expected GDP growth in Q4 FY25 at 7.4 per cent is an indicator that growth is rebounding which can lead to revival of corporate earnings in FY26, and foreign institutional investors (FIIs) are likely to continue their investment in India, analysts said on Saturday.

26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer ( MSS CRC ) without liver metastases

Stafford, Texas and Tuebingen, Germany, May 31, 2025 - Immatics N.V. ( NASDAQ: IMTX, "Immatics" or the "Company" ) , a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the presentation of expanded data ...

Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma 1

Washington, DC, May 31, 2025 ( GLOBE NEWSWIRE ) -- Global entrepreneurship education nonprofit Network for Teaching Entrepreneurship ( NFTE ) has named four local student businesses as the winners of its annual Capital Regional Youth Entrepreneurship Challenge.

PARIS, France, 31 May 2025 - Late-breaking ( LBA4175 ) post-hoc analysis data from the Phase III NAPOLI 3 study were presented today at the 2025 American Society of Clinical Oncology ( ASCO ) Annual Meeting. These results found a median overall survival ( mOS ) of 19.5 months among long-term ...

NEW HAVEN, Conn. and NEW YORK, May 31, 2025 ( GLOBE NEWSWIRE ) -- Arvinas, Inc. ( Nasdaq: ARVN ) and Pfizer Inc. ( NYSE: PFE ) today announced detailed results from the Phase 3 VERITAC-2 clinical trial ( NCT05654623 ) evaluating vepdegestrant monotherapy versus fulvestrant in adults with ...

This is a great time to consider adding quality dividend stocks to your investment portfolio. Recent headwinds in the economy have weighed on sales of leading retail and consumer goods brands, and this has driven their stocks down and their yields higher.While the near term could be rocky, ...

• Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing deep and durable objective responses up to >2.5 years • IMA203 PRAME cell therapy one-time ...